Our previous study found that YRDC promotes the proliferation of HCC cells via regulating the activity of the RAS/RAF/MEK/ERK pathway, which was the primary pathway of anticancer effect of lenvatinib. Here, YRDC is linked to hepatocellular carcinoma.